Long-lasting antinociceptive effects of green light in acute and chronic pain in rats MM Ibrahim, A Patwardhan, KB Gilbraith, A Moutal, X Yang, LA Chew, ... Pain 158 (2), 347-360, 2017 | 123 | 2017 |
Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral κ-opioid receptors TW Vanderah, T Largent-Milnes, J Lai, F Porreca, RA Houghten, ... European journal of pharmacology 583 (1), 62-72, 2008 | 113 | 2008 |
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss AN Lozano-Ondoua, C Wright, A Vardanyan, T King, TM Largent-Milnes, ... Life sciences 86 (17-18), 646-653, 2010 | 107 | 2010 |
Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists SA Grenald, MA Young, Y Wang, MH Ossipov, MM Ibrahim, ... Neuropharmacology 116, 59-70, 2017 | 102 | 2017 |
Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain Z Chen, TM Doyle, L Luongo, TM Largent-Milnes, LA Giancotti, G Kolar, ... Proceedings of the National Academy of Sciences 116 (21), 10557-10562, 2019 | 100 | 2019 |
Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated μ-opioid receptor–Gs coupling TM Largent-Milnes, W Guo, HY Wang, LH Burns, TW Vanderah The journal of pain 9 (8), 700-713, 2008 | 89 | 2008 |
Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists AN Lozano‐Ondoua, KE Hanlon, AM Symons‐Liguori, ... Journal of Bone and Mineral Research 28 (1), 92-107, 2013 | 85 | 2013 |
A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2. 2 trafficking and reverses inflammatory and postoperative pain behaviors L François-Moutal, Y Wang, A Moutal, KE Cottier, OK Melemedjian, ... Pain 156 (7), 1247-1264, 2015 | 83 | 2015 |
Analgesic potential of terpenes derived from Cannabis sativa E Liktor-Busa, A Keresztes, J LaVigne, JM Streicher, TM Largent-Milnes Pharmacological reviews 73 (4), 1269-1297, 2021 | 77 | 2021 |
A structure–activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are δ/μ opioid receptor agonists and neurokinin 1 … T Yamamoto, P Nair, J Vagner, T Largent-Milnes, P Davis, S Ma, ... Journal of medicinal chemistry 51 (5), 1369-1376, 2008 | 71 | 2008 |
Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance TM Largent‐Milnes, T Yamamoto, P Nair, JW Moulton, VJ Hruby, J Lai, ... British journal of pharmacology 161 (5), 986-1001, 2010 | 69 | 2010 |
Blocking CRMP2 SUMOylation reverses neuropathic pain A Moutal, ET Dustrude, TM Largent-Milnes, TW Vanderah, M Khanna, ... Molecular psychiatry 23 (11), 2119-2121, 2018 | 68 | 2018 |
A novel angiotensin-(1-7) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction M Hay, R Polt, ML Heien, TW Vanderah, TM Largent-Milnes, K Rodgers, ... The Journal of Pharmacology and Experimental Therapeutics 369 (1), 9-25, 2019 | 67 | 2019 |
Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation SA Grenald, TM Doyle, H Zhang, LM Slosky, Z Chen, TM Largent-Milnes, ... Pain 158 (9), 1733-1742, 2017 | 64 | 2017 |
Use of animal models in understanding cancer-induced bone pain LM Slosky, TM Largent-Milnes, TW Vanderah Cancer growth and metastasis 8, CGM. S21215, 2015 | 61 | 2015 |
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain BL Forte, LM Slosky, H Zhang, MR Arnold, WD Staatz, M Hay, ... Pain 157 (12), 2709-2721, 2016 | 58 | 2016 |
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist S Tumati, TM Largent-Milnes, A Keresztes, J Ren, WR Roeske, ... Journal of neuroimmunology 244 (1-2), 23-31, 2012 | 56 | 2012 |
Activation of descending pain-facilitatory pathways from the rostral ventromedial medulla by cholecystokinin elicits release of prostaglandin-E2 in the spinal cord TM Marshall, DS Herman, TM Largent-Milnes, H Badghisi, K Zuber, ... Pain 153 (1), 86-94, 2012 | 55 | 2012 |
Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain A Moutal, S Luo, TM Largent-Milnes, TW Vanderah, R Khanna Neurobiology of Pain 5, 100022, 2019 | 48 | 2019 |
Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain KE Hanlon, DS Herman, RS Agnes, TM Largent-Milnes, IR Kumarasinghe, ... Brain research 1395, 1-11, 2011 | 47 | 2011 |